T Cells Expressing a Bispecific CAR Targeting CS1 and BCMA in Relapsed/Refractory Multiple Myeloma

计划入组 24 人 · 首次发布于 2020 年 12 月 10 日

EMPOWER - BAME vs COVID

首次发布于 2020 年 5 月 22 日

BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM)

计划入组 34 人 · 首次发布于 2025 年 6 月 8 日

BCMA NKE

BG BCMA

BCMA ADC

ACME GENERICS PRIVATE LIMITED

India

THE ACME LABORATORIES LTD.

Bangladesh

BCM Resources Corp

Vaximm Secures Potential $835M Deal with BCM Europe for Oral Cancer Immunotherapy Platform VXM01

OSR Holdings Subsidiary Vaximm Secures $835M Licensing Deal for Oral Cancer Immunotherapy VXM01

GSK's BCMA-Targeting ADC, GSK2857916, Receives FDA Breakthrough Therapy Designation for Multiple Myeloma